Venturi Wealth Management LLC Purchases 5,821 Shares of Boston Scientific Co. (NYSE:BSX)

Venturi Wealth Management LLC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 323.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 7,620 shares of the medical equipment provider’s stock after buying an additional 5,821 shares during the period. Venturi Wealth Management LLC’s holdings in Boston Scientific were worth $681,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BSX. Northwest Investment Counselors LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $38,000. Raleigh Capital Management Inc. grew its stake in Boston Scientific by 11.7% in the 3rd quarter. Raleigh Capital Management Inc. now owns 5,360 shares of the medical equipment provider’s stock valued at $449,000 after buying an additional 560 shares during the last quarter. Waldron Private Wealth LLC grew its stake in Boston Scientific by 3.1% in the 3rd quarter. Waldron Private Wealth LLC now owns 5,098 shares of the medical equipment provider’s stock valued at $427,000 after buying an additional 152 shares during the last quarter. Pictet North America Advisors SA grew its stake in Boston Scientific by 1.4% in the 3rd quarter. Pictet North America Advisors SA now owns 76,290 shares of the medical equipment provider’s stock valued at $6,393,000 after buying an additional 1,032 shares during the last quarter. Finally, Stanley Laman Group Ltd. acquired a new position in Boston Scientific in the 3rd quarter valued at about $210,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Friday, January 10th. Piper Sandler increased their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Morgan Stanley increased their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Mizuho increased their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Finally, UBS Group increased their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. One analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $107.39.

Insider Activity at Boston Scientific

In other news, CFO Daniel J. Brennan sold 15,087 shares of the firm’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the transaction, the chief financial officer now owns 241,451 shares of the company’s stock, valued at approximately $25,369,256.57. This trade represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. The trade was a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 153,640 shares of company stock valued at $15,718,289 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $105.63 on Thursday. The company has a market cap of $155.68 billion, a price-to-earnings ratio of 84.50, a PEG ratio of 2.81 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a 50 day simple moving average of $97.39 and a 200 day simple moving average of $88.94. Boston Scientific Co. has a one year low of $65.33 and a one year high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.